IL-6 has been established as a reliable marker for the severity and mortality of COVID-19 in clinical practice, and its antagonist has been shown to reduce mortality in hospitalized COVID-19 patients [5,7,9,16,17,18,19]. Here, IL6 is linked to COVID-19.